Left Ventricular Assist Device (LVAD) Therapy in Cardiac Amyloidosis: Challenges and Feasibility
Table of Contents
Introduction
Cardiac amyloidosis (CA) is a serious, progressive, and potentially life-threatening condition due to the deposition of amyloid fibrils in the myocardium, resulting in restrictive cardiomyopathy and severe heart failure. Therapy has also progressed with disease-modifying treatments, but in the case of refractory heart failure, advanced mechanical circulatory support or heart transplantation are also an option.
One alternative is the left ventricular assist device (LVAD), a mechanical pump that aids in circulation for patients with end-stage heart failure. The place of LVAD therapy in cardiac amyloidosis, however, is unresolved, considering the specific structural and functional features of amyloid-infiltrated hearts.
This paper discusses the feasibility, obstacles, outcomes, and criteria for patient selection of LVAD therapy in cardiac amyloidosis with emphasis on its possible role in advanced management.
1. Cardiac Amyloidosis and Advanced Heart Failure: Understanding
- Definition: Cardiac amyloidosis is caused by amyloid protein deposits that stiffen ventricles, impair diastolic filling, and ultimately cause restrictive cardiomyopathy.
- Common forms:
- AL amyloidosis (immunoglobulin light-chain)
- ATTR amyloidosis (transthyretin-related; hereditary and wild-type)
- Course: Initial symptoms may be mimicked by other heart failure syndromes, but patients usually present late with refractory heart failure, arrhythmias, and conduction disturbances.
2. Standard Treatment Strategies Prior to LVAD Consideration
- Disease-modifying therapies:
- AL: chemotherapy, proteasome inhibitors, stem cell transplantation
- ATTR: tafamidis, patisiran, vutrisiran, inotersen
- Supportive therapy:
- Diuretics for congestion
- Anticoagulation for atrial fibrillation
- Digoxin and some beta-blockers avoidance
- Heart transplantation: considered in young, selected patients with only cardiac involvement
When medical treatment is unsuccessful and transplantation cannot be done, mechanical circulatory support with LVAD can be an option.
3. What Is LVAD Therapy?
- Definition: An LVAD is a mechanical pump implanted through surgery to help the left ventricle pump blood to the rest of the body.
- Uses:
- Bridge to transplantation
- Destination therapy (permanent support when transplantation is not possible)
- Advantages in usual heart failure: Enhanced survival, quality of life, and exercise tolerance
4. LVAD Therapy in Cardiac Amyloidosis: Why Is It Difficult?
While dilated cardiomyopathy is a condition in which LVAD therapy is standard, CA has special challenges:
- Restrictive physiology: Small, rigid ventricles restrict device inflow.
- Small size of the ventricular cavity: Potential for suction events and failure of the device.
- Increased risk of right ventricular failure: Because amyloid deposition involves biventricular involvement.
- Coagulopathy: Patients might already have a tendency to bleed or clot.
- Multisystem involvement: Renal, hepatic, and neurological amyloid complicates perioperative management.
These issues make LVAD implantation viable in only a highly selected group of patients.
5. Patient Selection for LVAD in Cardiac Amyloidosis
Ideal Candidates:
- Refractory advanced heart failure to medical therapy
- Primarily cardiac involvement with minimal extracardiac disease
- Satisfactory right ventricular function (to avoid early RV failure after LVAD)
- Patients undergoing heart transplantation (bridge-to-transplant strategy)
Poor Candidates: - Severe multiorgan amyloid involvement
- Extreme frailty or cachexia
- Severe right ventricular dysfunction
6. Surgical and Technical Considerations
*
- Ventricular cavity preparation: Surgeons should accommodate techniques for small LV size.
- Choice of device: Continuous-flow LVADs are usually favored.
- RV support: Some patients may need biventricular assist devices (BiVAD).
- Bleeding risk: High awareness for anticoagulation complication.
7. Outcomes of LVAD Therapy in CA Patients
Evidence is limited but increasing:
- Feasibility: A number of case series of successful LVAD support in CA patients.
- Complications:
- Excessive rates of right heart failure
- Bleeding and thromboembolic events increased
- Survival: Lower than with dilated cardiomyopathy, although some benefit greatly as a bridge to transplant.
- Quality of life: Improved in well-selected patients.
In general, LVAD outcomes are variable, and individualized decision-making is crucial.
8. LVAD as Bridge to Heart Transplantation
- Bridge-to-transplant role: LVAD could stabilize CA patients pending donor hearts.
- Challenges: Only if systemic amyloid burden is low and hematologic control (in AL) is obtained.
- Sequential approach: In AL amyloidosis, patients can be treated with heart transplantation followed by stem cell transplant for management of plasma cell disease.
9. LVAD as Destination Therapy in CA
- Infrequently used: Because of progression of systemic disease.
- Possible role: In nontransplantable patients with single-advanced cardiac disease and favorable RV function.
- Limitations: Results are usually dismal due to progression of extracardiac amyloidosis even with LVAD support.
10. Future Directions
- Improved patient selection: Advanced imaging (cardiac MRI, nuclear imaging) will allow selection of appropriate LVAD candidates.
- Device innovation: Design of pumps tailored to restrictive cardiomyopathy physiology.
- Combination therapies: LVAD support with gene-silencing or new amyloid-targeting medications could enhance outcomes.
- Clinical trials: Required to create more definitive guidelines for LVAD in CA.
11. Patient Counseling and Support
- Shared decision-making: Risks and benefits should be explained to patients and families.
- Multidisciplinary approach: Participation from cardiologists, hematologists, and transplant surgeons.
- Palliative considerations: In non-candidates, symptom management and quality of life become the concern.
Conclusion
LVAD treatment for cardiac amyloidosis is still a controversial and difficult intervention. Though technically possible, it is opposed by restrictive physiology, diminutive ventricular cavities, right ventricular failure, and systemic amyloid disease.
In appropriately selected patients, as a bridge to transplantation, LVADs can provide significant survival and symptomatic improvement. It remains limited as destination therapy due to poor long-term results, however.
The future could include enhanced patient selection, device design, and coupling with disease-modifying therapies that could serve to further accelerate the role of LVADs in this challenging disease.